Literature DB >> 11139203

Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.

F D Cordeiro1, O A Martins-Filho, M O Da Costa Rocha, S J Adad, R Corrêa-Oliveira, A J Romanha.   

Abstract

Two functionally distinct antibodies, categorized as conventional serology antibodies (CSA) and lytic antibodies (LA) have been described in Chagas' disease, based on their ability to bind to fixed epimastigotes (EPI) or live trypomastigotes (TRYPO), respectively. In this study, the profile of immunoglobulin G (IgG) subclasses of CSA and LA were analyzed by flow cytometry using serum samples from chronic chagasic patients with the indeterminate (IND), cardiac (CARD), and digestive (DIG) clinical forms of the disease. The results were expressed as percentage of positive fluorescent parasites (PPFP) for each sample. CSA showed a higher PPFP than LA for all samples. At serum dilutions between 1:256 and 1:2,048, IgG1 anti-EPI was able to distinguish chagasic from nonchagasic individuals. Different profiles of IgG subclasses were observed for CSA and LA. IgG1 and IgG2 were the main subclasses in CSA, whereas IgG1 and IgG3 were the predominant ones in LA. The reactivity of IgG2 anti-EPI was greater in IND and CARD than in DIG patients. Furthermore, a low level of IgG1 and IgG3 LA was associated with most of the CARD patients. On the other hand, a high level of IgG1 LA was associated with most of the IND patients. In summary, our findings indicate the potential of IgG1 anti-EPI for serological diagnosis of Chagas' disease, providing further evidence for a protective role of LA, and show that IgG1 anti-live Trypanosoma cruzi TRYPO may be used to predict the risk of cardiac damage in Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139203      PMCID: PMC96018          DOI: 10.1128/CDLI.8.1.112-118.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Control of Chagas disease. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1991

2.  [Study of cases of leishmaniasis in the Province of Salta: evidences of mixed infection with Trypanosoma cruzi and Leishmania spp].

Authors:  M G Chiaramonte; N W Zwirner; S L Caropresi; V Heredia; N J Taranto; E L Malchiodi
Journal:  Medicina (B Aires)       Date:  1996       Impact factor: 0.653

3.  Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease.

Authors:  J Morgan; J C Dias; E D Gontijo; L Bahia-Oliveira; R Correa-Oliveira; D G Colley; M R Powell
Journal:  Am J Trop Med Hyg       Date:  1996-10       Impact factor: 2.345

Review 4.  Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

Authors:  Z Brener; R T Gazzinelli
Journal:  Int Arch Allergy Immunol       Date:  1997-10       Impact factor: 2.749

5.  Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease.

Authors:  I C Almeida; G M Krautz; A U Krettli; L R Travassos
Journal:  J Clin Lab Anal       Date:  1993       Impact factor: 2.352

6.  Cross-reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6).

Authors:  E L Malchiodi; M G Chiaramonte; N J Taranto; N W Zwirner; R A Margni
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

7.  Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease.

Authors:  O A Martins-Filho; M E Pereira; J F Carvalho; J R Cançado; Z Brener
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 8.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

9.  Antibody isotypes profiles against Trypanosoma cruzi acidic antigens in two Amerindian populations from a Chagas' disease endemic area.

Authors:  C C Motran; H M Serra; S E Gea; C M Vullo; E Vottero-Cima
Journal:  Acta Trop       Date:  1994-11       Impact factor: 3.112

10.  Specificity and role of anti-Trypanosoma cruzi clearance antibodies.

Authors:  L F Umekita; K C Barbaro; I Mota
Journal:  Braz J Med Biol Res       Date:  1996-01       Impact factor: 2.590

View more
  23 in total

1.  Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Trypanosoma cruzi Infection in Mice.

Authors:  Karl V Clemons; Raymond A Sobel; Marife Martinez; Rodrigo Correa-Oliveira; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

Review 2.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

3.  Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.

Authors:  Olindo Assis Martins-Filho; Silvana Maria Eloi-Santos; Andréa Teixeira Carvalho; Rodrigo Corrêa Oliveira; Anis Rassi; Alejandro Ostemayer Luquetti; Gustavo Gabriel Rassi; Zigman Brener
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  Vaccine       Date:  2012-10-15       Impact factor: 3.641

Review 5.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

6.  Perforin-expressing cytotoxic cells contribute to chronic cardiomyopathy in Trypanosoma cruzi infection.

Authors:  Jaline Coutinho Silverio; Luzia Maria de-Oliveira-Pinto; Andréa Alice da Silva; Gabriel Melo de Oliveira; Joseli Lannes-Vieira
Journal:  Int J Exp Pathol       Date:  2009-10-28       Impact factor: 1.925

7.  Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes.

Authors:  Max Jean de Ornelas Toledo; Maria Terezinha Bahia; Cláudia M Carneiro; Olindo Assis Martins-Filho; Michel Tibayrenc; Christian Barnabé; Washington Luis Tafuri; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Combined use of enzyme-linked immunosorbent assay and flow cytometry to detect antibodies to Trypanosoma cruzi in domestic canines in Texas.

Authors:  Sean V Shadomy; Stephen C Waring; Olindo Assis Martins-Filho; Rodrigo Corrêa Oliveira; Cynthia L Chappell
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.

Authors:  H R Martins; R Moreira Silva; H M S Valadares; M J O Toledo; V M Veloso; D M Vitelli-Avelar; C M Carneiro; G L L Machado-Coelho; M T Bahia; O A Martins-Filho; A M Macedo; M Lana
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

10.  Chagas' disease: IgG isotypes against cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens of Trypanosoma cruzi in chronic Chagasic patients.

Authors:  A F A Verçosa; V M B Lorena; C L Carvalho; M F A D Melo; M G A Cavalcanti; E D Silva; A G P Ferreira; V R A Pereira; W V Souza; Y M Gomes
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.